NanoViricides Reports NV-387 Shows Strong Antiviral Activity Against Measles in Preclinical Studies
NanoViricides' clinical lead drug candidate NV-387 demonstrated potent antiviral effects against Measles virus with significant lung protection and extended survival in animal models, potentially offering the first approved treatment for a disease that currently has no specific antiviral therapy.
NanoViricides, Inc. (NYSE American: NNVC) announced that its clinical lead drug candidate, NV-387, demonstrated potent antiviral effects against the Measles virus in both cell culture studies and a humanized animal model. The treatment extended survival in infected mice by 130%, from 7.4 to 17 days, while significantly protecting lung tissue from viral and immune-related damage.
The drug's dual action—direct viral suppression and mitigation of systemic and lung inflammation—showed reduced lung plaques, slower disease progression and improved overall health outcomes in treated animals. Currently, no approved drug exists for Measles treatment, underscoring NV-387's potential as a first-in-class therapeutic candidate. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-387 represents a broad-spectrum antiviral drug that NanoViricides plans to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company's platform technology and programs are based on the TheraCour nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel.
NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of multiple human viral diseases. The company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. More information about the company is available at https://www.nanoviricides.com.
The company is also developing drugs against a number of other viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. As with any drug development efforts, there can be no assurance at this time that any of the company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development.